Access to anti-retroviral drugs, female in Somalia

Somalia: Access to anti-retroviral drugs, female was 70.0% in 2024. ◆ Volatile

Latest (2024)
70.0%
Change on year
up 6.1%
World rank
82nd
of 141 countries
All-time high
70.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Somalia, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 0 %2006: 1 %2007: 2 %2008: 4 %2009: 6 %2010: 9 %2011: 14 %2012: 18 %2013: 25 %2014: 26 %2015: 32 %2016: 36 %2017: 41 %2018: 44 %2019: 48 %2020: 51 %2021: 56 %2022: 59 %2023: 66 %2024: 70 %

Source: UNAIDS estimates. Measured in %.

Analysis

Somalia recorded 70.0% for access to anti-retroviral drugs, female in 2024. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 6.1% on the previous year and up 169.2% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Somalia peaked at 70.0% in 2024 and was at its lowest, 0.0%, in 2000.

Somalia ranks 82nd of 141 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Somalia, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Somalia, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 0.0%
2006 1.0%
2007 2.0% +100.0%
2008 4.0% +100.0%
2009 6.0% +50.0%
2010 9.0% +50.0%
2011 14.0% +55.6%
2012 18.0% +28.6%
2013 25.0% +38.9%
2014 26.0% +4.0%
2015 32.0% +23.1%
2016 36.0% +12.5%
2017 41.0% +13.9%
2018 44.0% +7.3%
2019 48.0% +9.1%
2020 51.0% +6.2%
2021 56.0% +9.8%
2022 59.0% +5.4%
2023 66.0% +11.9%
2024 70.0% +6.1%

Averages by decade

DecadeAverage LowestHighest Years
2000s 1.3% 0.0% 6.0% 10
2010s 29.3% 9.0% 48.0% 10
2020s 60.4% 51.0% 70.0% 5

Countries ranked near Somalia

  1. 81 Lao People's Democratic Republic 71.0% compare
  2. 82 Estonia 70.0% compare
  3. 84 Lebanon 69.0% compare
  4. 84 Serbia 69.0% compare

See the full ranking of 160 places →

More gender data for Somalia

All data for Somalia →

Frequently asked questions

What is access to anti-retroviral drugs, female in Somalia?
Access to anti-retroviral drugs, female in Somalia was 70.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Somalia?
The highest recorded value was 70.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Somalia?
The lowest recorded value was 0.0% in 2000.
How does Somalia rank for access to anti-retroviral drugs, female?
Somalia ranks 82nd out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Somalia?
Over the last ten years it is up 169.2%. The long-run trend across the full record is volatile.
Where does this Somalia data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Somalia. Statizoid, drawing on UNAIDS estimates. Retrieved 11 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/somalia-fed-rep/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/somalia-fed-rep/">Access to anti-retroviral drugs, female in Somalia</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.